David Reeser is one of the millions of Americans whose life has been changed by the ever-evolving, fast-growing epidemic of ...

Charles E. Hamner, Jr., Pd.D., the second president and CEO of the North Carolina Biotechnology Center and a longtime advocate for life sciences in the state, has received the 2024 High Flyer Champion ...

Research Triangle Park-based Opus Genetics, a clinical-stage gene therapy company devoted to treating inherited retinal diseases, has been acquired by a small ophthalmic biopharmaceutical firm with ...

Radiopharmaceuticals, once a very niche drug class, are now on the brink of transforming cancer treatment and diagnostics, and North Carolina is at the heart of this change. These radioactive drugs ...

Life sciences companies from around the state, nation and world are expanding their capacity to manufacture pharmaceuticals and biological therapies in North Carolina. Expansions announced in 2020 ...

That message is abundantly clear in the newly published analysis, "Evidence & Opportunity 2022: Impact of Life Sciences in NC," which documents why North Carolina continues to garner global admiration ...

Life sciences manufacturing is getting a $30 million boost in Eastern North Carolina, thanks to a state budget appropriation to develop a biologics training center in Wilson. The center will provide ...

Durham-based Locus Biosciences has received $23.9 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to begin a blinded, placebo-controlled clinical trial of ...

SCHOTT Pharma USA, Inc., part of SHOTT Pharma AG, a global specialty glass manufacturer based in Germany, plans to invest $371 million over the next five years to build a new production facility in ...

The U.S. National Science Foundation on Friday announced two of the first-ever NSF Regional Innovation Engines (NSF Engines), both in North Carolina. The Piedmont Triad Regenerative Medicine Engine ...

Durham-based EydisBio Inc. has received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for EYD-001, a treatment for systemic sclerosis. This rare and debilitating ...

“Could it be small enough to be flown?” an investor asked out of the audience. “With the proper funding!” responded the entrepreneur on stage, to chuckles and knowing smiles around the auditorium.